Recombinant adeno-associated virus-mediated human kallikrein gene therapy protects against hypertensive target organ injuries through inhibiting cell apoptosis

Acta Pharmacologica Sinica

Volumn 30, Issue 9, 2009, Pages 1253-1261

  Yan, Jiang Tao ^a   Wang, Tao ^a   Wang, Dao Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; Gene therapy; Hypertension; Kallikrein; Recombinant adeno associated virus; Target organs injuries

Indexed keywords

BETA GALACTOSIDASE; CASPASE 3; KALLIKREIN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PARVOVIRUS VECTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA INJURY; APOPTOSIS; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; HEART INJURY; HUMAN; HUMAN CELL; KIDNEY INJURY; MALE; NONHUMAN; RAT; SIGNAL TRANSDUCTION; TARGET ORGAN;

ANIMALS; APOPTOSIS; CASPASE 3; DEPENDOVIRUS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE THERAPY; GENETIC VECTORS; HUMANS; HYPERTENSION; KALLIKREIN-KININ SYSTEM; KALLIKREINS; RATS; RATS, INBRED SHR;

EID: 70249110037     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.114     Document Type: Article

References (29)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The National High Blood Pressure Education Program Coordinating Committee. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206-1252
2. Phillips MI. Gene therapy for hypertension: The preclinical data. Hypertension 2001; 38: 543-548
3. Monahan PE, Samulski RJ. AAV vectors: is clinical success on the horizon? Gene Ther 2000; 7: 24-30.
4. Mueller C, Flotte TR. Clinical gene therapy using recombinant adenoassociated virus vectors. Gene Ther 2008; 15: 858-863
5. Chao J, Chao L. Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp Physiol 2005; 90: 291-298
6. Wang T, Li H, Zhao C, Chen C, Li J, Chao J, et al. Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries. Gene Ther 2004; 11: 1342-1350
7. Wang T, Hou L, Liu Z, Wang Y, Chen C, Xiao X, et al. Intramuscular delivery of raav-mediated kallikrein gene reduces hypertension and prevents cardiovascular injuries in model rats. Acta Pharmacol Sin 2007; 28: 1898-1906.
8. Yan J, Wang T, Li J, Xiao X, Wang D. Recombinant adeno-associated virus-mediated human kallikrein gene therapy prevents high-salt diet-induced hypertension without effect on basal blood pressure. Acta Pharmacol Sin 2008; 29: 808-814
9. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adenoassociated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232
10. Kramarenko II, Bunni MA, Morinelli TA, Raymond JR, Garnovskaya MN. Identification of functional bradykinin B2 receptors endogenously expressed in HEK293 cells. Biochem Pharmacol 2009; 77: 269-276
11. Hamet P, Richard L, Dam TV, Teiger E, Orlov SN, Gaboury L, et al. Apoptosis in target organs of hypertension. Hypertension 1995; 26: 642-648
12. Gonzalez A, Fortuno MA, Querejeta R, Ravassa S, Lopez B, Lopez N, et al. Cardiomyocyte apoptosis in hypertensive cardiomyopathy. Cardiovasc Res 2003; 59: 549-562
13. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 1997; 29: 859-870
14. Diep QN, El Mabrouk M, Yue P, Schiffrin EL. Effect of at1 receptor blockade on cardiac apoptosis in angiotensin ii-induced hypertension. Am J Physiol Heart Circ Physiol 2002; 282: H1635-41.
15. Gonzalez A, Lopez B, Ravassa S, Querejeta R, Larman M, Diez J, et al. Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. Hypertension 2002; 39: 75-80.
16. Messadi-Laribi E, Griol-Charhbili V, Pizard A, Vincent MP, Heudes D, Meneton P, et al. Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia. J Pharmacol Exp Ther 2007; 323: 210-216
17. Westermann D, Schultheiss HP, Tschöpe C. New perspective on the tissue kallikrein-kinin system in myocardial infarction: role of angiogenesis and cardiac regeneration. Int Immunopharmacol 2008; 8: 148-154
18. Yin H, Chao L, Chao J. Kallikrein/Kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad{middle dot}14-3-3 signaling pathways. J Biol Chem 2005; 280: 8022-8030
19. Messadi-Laribi E, Griol-Charhbili V, Gaies E, Vincent MP, Heudes D, Meneton P, et al. Cardioprotection and kallikrein-kinin system in acute myocardial ischaemia in mice. Clin Exp Pharmacol Physiol 2008; 35: 489-493
20. Chao J, Bledsoe G, Yin H, Chao L. The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. Biol Chem 2006; 387: 665-675
21. Bledsoe G, Crickman S, Mao J, Xia CF, Murakami H, Chao L, et al. Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Neprol Dial Transplant 2006; 21: 624-633 (Pubitemid 43372907)
22. Tu L,Xu X,Wan H,Zhou C,Deng J,Xu G, et al. Delivery of recombinant adeno-associated virus-mediated human tissue kallikrein for therapy of chronic renal failure in rats. Hum Gene Ther 2008; 19: 318-330
23. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: Roles www.chinaphar.com Yan JT et al of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38: 581-587
24. Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000; 87: 179-183
25. Pollman MJ, Yamada T, Horiuchi M, Gibbons GH. Vasoactive substances regulate vascular smooth muscle cell apoptosis: countervailing influences of nitric oxide and angiotensin II. Circ Res 1996; 79: 748-756
26. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 1996; 93: 156-160
27. Cattaruzza M, Dimigen C, Ehrenreich H, Hecker M. Stretch-induced endothelin B receptor-mediated apoptosis in vascular smooth muscle cells. FASEB J 2000; 14: 991-998
28. Jeong SY, Seol DW. The role of mitochondria in apoptosis. BMB Rep 2008; 41: 11-22.
29. Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene 2008; 27: 6194-6206